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1.  A national population health survey program using physical and 
biochemical measures is proposed for Australia.  The Australian Health 
Measurement Survey program (AHMS) offers a number of new opportunities 
to provide a sound, current information base for future national health policy 
development, health program planning and health research in ways that have 
not previously been possible.  
 
2.  Survey programs of this nature have been conducted for many years in the 
USA, some European and Asian countries, the United Kingdom and, more 
recently, in New Zealand and serve as the base to support health policy, 
health research and prevention strategies in those countries. 
 
3.  In Australia, there has been an investment by governments and others in 
the collection of health information and concomitant biochemical and other 
measures, but the majority of those studies are no longer current, leaving 
significant gaps in our knowledge of the health of the population.  The 
National Heart Foundation’s surveys of risk factors were conducted in all 
capital cities in the 1980s and provided the first population data on risk of 
cardiovascular disease.  In 1999, the International Diabetes Institute (IDI) 
received funding for a large study into the prevalence of diabetes and 
cardiovascular disease and associated risk factors (The Australian Diabetes, 
Obesity and Lifestyle Study (AusDiab)).  The AHMS program will build upon 
this investment, and the lessons from these studies.  
 
4.  Without current data on diseases, risk factors and other health 
determinants, information about the Australian population's health and 
functional ability is inadequate.  Time trends of risk and protective factors for 
chronic diseases are unavailable. There is little information about the factors 
that are important for family health and nutrition.  More needs to be known 
about the determinants of health and their effects on the age-trends of health 
and functional capacity. 
 
5.  The measures to be included in the AHMS program are crucial for the 
development and monitoring of services for conditions which have been 
responsible for at least two-thirds of the mortality gain in the last 30 years, 
and which still offer the greatest prospects for mortality gain in the future – 
especially the National Health Priority Areas of circulatory conditions and 
diabetes, but there are also implications for major cancers. 
 
6. To obtain the necessary information to underpin health policy and 
program development, there is a need for health measurement surveys to be 
carried out at regular intervals and to include a broad range of measures.  The 
proposed AHMS program will provide an up-to-date, comprehensive picture 
of health in the population by studying the prevalence and determinants of 
 most significant health problems and the associated need for prevention, care 
and rehabilitation. Information will also be collected on health determinants 
and on health disparities between population groups and geographic regions. 
Time trends of adult health will be assessed by comparing the findings with 
earlier data.  This information is currently unavailable to health policy-makers 






































































NHSAustralian Health Measurement Survey (AHMS) Program 
 
Outline of the proposal 
osed that a series of cross-sectional health measurement surveys, 
clude physical and biochemical measures of health status and 
lly modifiable risk factors and determinants of health, be conducted 
ears in association with every second Australian Bureau of Statistics 
ational Health Survey. 
vey would provide much needed population health data to inform 
d interventions on priority health problems such as diabetes, 
scular disease, hypertension, hypercholesterolaemia, and other 
diseases that have significant economic, health and social impact. 
 AHMS would: 
nducted in conjunction with the 2004/5 ABS National Health Survey. 
de physical measurement and the collection of data on a range of 
se outcomes and risks. 
ationally representative of Australians of different ages, sex, 
raphic area and socioeconomic circumstances. 
r the age range 2 to 74 years, with appropriate consent procedures 
ll participants. 
sure height; weight; abdominal circumference; blood pressure; blood 
lesterol and lipid levels, homocysteine, fasting glucose, glycosylated 
oglobin and insulin) and possibly other biological markers. 
eveloped by the Commonwealth Department of Health and Ageing, 
ustralian Institute of Health and Welfare and the ABS. 
nderpinned by wide consultation on ethical issues, with final ethical 
oval to be sought from the AIHW Ethics Committee. 
iloted in February 2003. 
 approximately $7.2 million excluding GST for a survey linked to the 
. viii 
lia’s National Public Health Information Development Plan 
d by the Australian Health Ministers Advisory Council (AHMAC) in 
s developed ‘to identify the action needed to improve public health 
ion in Australia’.  One of its identified components was the need for 
opment of a national biomedical risk factor or health measurement 
IHW & NPHIWG 1999, Recommendation 1.1.1).   
stantial amount of planning and research is needed in order to 
at the significant investment of money required for surveys of this 
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kind is realised in valuable and useful results that lead to better health 
strategies for the population, and that wide support is built for the survey 
program from the start.  This approach has been adopted for Australia. 
 
9.  A developmental process was undertaken with an Inter-Governmental 
Steering Committee (with membership from the (now) Commonwealth 
Department of Health and Ageing (DoHA), the Australian Institute of Health 
and Welfare (AIHW), the Australian Bureau of Statistics (ABS) and 
State/Territory jurisdictions; see page xi) and a scientific Reference Group 
(see page xiii).  Both structures were necessary to ensure a national 
perspective regarding policy input from across all jurisdictions and technical 
expert advice on the survey design, content and methodology.  This proposal 
is the result of their deliberations and of wider consultations within their 
jurisdictions.  
 
10.  The proposed AHMS program has been developed as a program of cross-
sectional surveys that include a component of physical and biochemical 
measurement, and will examine a range of disease outcomes and risks.  It will 
be nationally representative of people of different ages, sex, geographic area 
and socioeconomic circumstances.  It will combine questionnaire answers and 
physical and biochemical measures (such as measurement of height and 
weight; analyses of samples of blood, urine, and saliva; and tests of function).  
 
11.  The AHMS program has been designed to be policy relevant and to 
maximise related research and development opportunities for policy-makers 
and health researchers.  The program allows for the inclusion of a wider range 
of content areas than a single ‘stand-alone’ survey, and will include 
respondents from the ages of two to 74 years.   
 
12.  The AHMS program is recommended to commence in association with 
the Australian Bureau of Statistics’ National Health Survey (ABS NHS) in 
2004/5.  There are two parts to the linked NHS/AHMS program.  The first of 
these contains the subjective questions in the NHS.  The second part 
comprises the physical and biochemical measures undertaken in the AHMS.  
It is proposed that the AHMS be repeated after six years, with the possibility 
of more frequent surveys, once the initial results have been analysed and their 
contribution to policy development, program planning and research assessed.  
The decision to link the AHMS program with the NHS will allow validation 
of the subjective, self-reported data that is collected in the NHS.  The conduct 
of the AHMS with the NHS also represents a considerable cost saving, as 
compared to the cost of a ‘stand-alone’ health measurement survey program. 
 
13.  Work with the ABS on the AHMS program development resulted in a 
skirmish being undertaken in November 2001 to assess initial elements of the 
recruitment process to AHMS.  Preliminary results indicate adequate 
response rates that are similar to surveys of this kind overseas.  A full pilot 
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test is now required to test all aspects of the survey process, including the 
taking of measures. 
14.  The survey program is strongly supported by the divisions of the DoHA, 
the AIHW and the ABS.  The States and Territories have also indicated high-
level support and interest, particularly in broad, policy relevant content 
coverage. Firm support has also been received from the scientific Reference 
Group, comprising leading health academics, advising the AHMS Inter-
Governmental Steering Committee. 
 
15.  It is envisaged that the cost of the first survey would be $6.3 million 
(excluding GST) over six years.  With the inclusion of Departmental costs and 
the costs for the management of the survey contract, the total cost rises to $7.2 
million. An annual allocation of $1.2 million would support developmental 
costs, data collection, analysis and reporting for an ongoing survey program. 
It is expected that the benefits of this investment would far outweigh the costs 
incurred, through better-informed policy formulation and program planning.   
 
16.  Up-to-date information on the population's health is critical for informed 
decision-making and, to date, comprehensive health data have not been 
collected regularly in Australia.  A lack of information hampers health policy 
and planning.  Research on health promotion and disease prevention suffers 
from the absence of timely data and information on the population's health, 
health risks and their determinants.  The information obtained by the AHMS 
program is an essential basis for national health policy formulation and health 
planning for the next decades.  This national survey program will also have 
the advantage of reducing the need for ad hoc health data collecting activities.  
 xi 
TERMS OF REFERENCE 
 
The Inter-Governmental Steering Committee will oversee the survey’s 
development and will be required to: 
 
 Identify the strategic policy areas and health issues that would benefit 
from information derived from a national population health survey 
with physical and biochemical measures; 
 
 Examine, assisted by advice from the Reference Group, the 
methodological, legal and ethical factors related to the survey’s design; 
 
 Examine the issues related to the end use of the survey data; and, 
 
 Develop a business case containing recommendations regarding the 
feasibility, scope, content and funding of a national population health 
survey with physical and biochemical measures, prior to the meeting 
of AHMAC in February 2001. 
 
The Inter-Governmental Steering Committee endorsed these terms of 
reference in March 2000.  As a result of the additional time required for 
consultation, the final term of reference was amended in September 2001 to 
‘May 2002’ (instead of ‘February 2001’). 
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1.  A NATIONAL HEALTH MEASUREMENT SURVEY PROGRAM 
FOR AUSTRALIA   
 
A national population health survey program using physical and biochemical measures 
is proposed for Australia. The Australian Health Measurement Survey program 
(AHMS) offers a number of new opportunities to provide a sound, current information 
base for future national health policy development, health program planning and 
health research in ways that have not previously been possible.  
 
The AHMS program, recommended to commence in association with the Australian 
Bureau of Statistics’ National Health Survey (ABS NHS) program in 2004/5, will 
complement the subjective information collected by the NHS with the collection of 
more objective health measures for the Australian population.  
 
1.1   Background  
 
1.1.1   Primary reasons for undertaking national population health surveys using 
physical and biochemical measures 
Monitoring and forecasting the population's health and health determinants are 
prerequisites for knowledge-based health policy and the development of health care at 
national, regional and local levels. National health measurement surveys are 
characterised by the collection of subjective information through questionnaires, and 
the gathering of more objective information via measurement of height, weight and 
body mass; factors in saliva, blood and/or urine; lung function; mental health and 
cognitive state; or childhood development.  
  
From an examination of the use of surveys of this type that have been undertaken 
around the world, the following purposes have been identified:   
 the monitoring within a population of certain high priority health goals and targets 
relating to the prevention of various diseases or conditions at one point in time, and 
over time as surveys are repeated regularly; 
 the provision of baseline data related to particular health issues or policies; 
 the contribution to particular research questions about health and related conditions 
and their treatment or eradication; 
 the surveillance of infective agents or other factors that impact negatively on the 
population’s health or may do so in the future; and 
 the collection of information at a population level - to assist in the development of 
policy and planning of services or determining need, to assess the degree of success 
of health promotion or illness prevention strategies and to contribute to a greater 
understanding of health and illness.   
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Survey programs of this nature have been conducted for many years in the USA, some 
European and Asian countries, the United Kingdom and, more recently, in New 
Zealand, and serve as the base to support health policy, health research and prevention 
strategies in those countries. 
 
1.1.2  The AHMS program and its place in the longer term direction of national 
population health information development 
There has been an investment by governments and others in the collection of health 
information and concomitant biochemical and other measures in Australia, but the 
majority of those studies are no longer current, leaving significant gaps in our 
knowledge of the health of the population.  The National Heart Foundation’s surveys of 
risk factors were conducted in all capital cities in the 1980s and provided the first 
‘national’ population data on risk of cardiovascular disease.  In 1999, the International 
Diabetes Institute (IDI) received funding for a large study into the prevalence of 
diabetes and cardiovascular disease and associated risk factors (The Australian 
Diabetes, Obesity and Lifestyle Study (AusDiab)).  However, issues have been raised 
regarding the accuracy of estimates produced in the study because of the sample design 
and sub-optimal response rates. 
 
To obtain the necessary information to underpin health policy and program 
development, there is a need for these health surveys to be carried out at regular 
intervals and to include a comprehensive range of measures. Without current data on 
diseases, risk factors and other health determinants, information about the Australian 
population's health and functional ability is inadequate. There is little information 
about the factors that are important for family health and nutrition. Time trends of risk 
and protective factors for chronic diseases are unavailable. Information on health 
determinants needs to be gathered simultaneously with information on health and 
functional capacity, and more needs to be known about the effects of these 
determinants on health and on the age-trends of health and functional capacity. 
 
The main aim of the proposed AHMS program is to provide an up-to-date, 
comprehensive picture of health in the population by studying the prevalence and 
determinants of most significant health problems and the associated need for 
prevention, care and rehabilitation. This information is currently unavailable to health 
policy-makers and researchers in Australia.  
 
The AHMS program will gather physical and biochemical information on the 
population’s health. Information will also be collected on health determinants and on 
health disparities between population groups and geographic regions.  Time trends of 
adult health will be assessed by comparing the findings with earlier data.  
 
Forecasts concerning the future need for health care will use AHMS information as a 
starting point.  It can be expected that in the period when the baby boom cohort move 
into older age groups (a person born in 1946 will be 65 years old in 2011), there will be 
ever-increasing pressures on the Australian health system and an urgent need for 
accurate population health information.  Therefore the AHMS surveys in 2004/5, 
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2010/11 and 2016/17, will provide a substantial information building block for the 
Australian health system in the decades ahead.   
 
Up-to-date information on the whole population's health is critical for informed 
decision-making and, to date, comprehensive health data have not been collected 
regularly in Australia.  A lack of information hampers health policy and planning.  
Research on health promotion and disease prevention suffers from the absence of 
timely data and information on the population's health, health risks and their 
determinants.  The information obtained by the AHMS program is an essential basis for 
national health policy formulation and health planning for the next decades.  This 
national survey program will also have the advantage of reducing the need for ad hoc 
health data collecting activities.  
 
1.2   Overview of the developmental process undertaken 
 
National population health surveys containing a component of physical and 
biochemical measurement have been used both in Australia and overseas to add to the 
information about the state of health of a population and to complement research into 
particular issues, diseases or directions in health policy. Australia’s National Public 
Health Information Development Plan (endorsed by AHMAC in 1999) was developed 
‘to identify the action needed to improve public health information in Australia’.  One 
of its identified components was the need for the development of a national biomedical 
risk factor or health measurement survey, subject to piloting to confirm that adequate 
response rates could be achieved (Recommendation 1.1.1).   
 
To this end, the Australian Institute of Health and Welfare (AIHW) undertook initial 
planning and costing for such a survey and a proposal was submitted to AHMAC in 
1999.  However in November 1999, the National Public Health Partnership (NPHP), on 
the advice of AIHW and the National Public Health Information Working Group 
(NPHIWG), endorsed the need for further development of a business case for the 
survey (formerly called the “National Biomedical Risk Factor Survey”).  It was agreed 
that the (now) Department of Health and Ageing (DoHA) would take the lead, in 
partnership with the AIHW and with the involvement of all jurisdictions and the ABS.   
 
An Inter-Governmental Steering Committee was established, reporting to the NPHP, 
with Commonwealth, AIHW, ABS and State/Territory membership (see page xi).  The 
role of the Steering Committee was to guide the progress of the survey development.  A 
Reference Group was also established to provide expert technical advice to DHAC, 
AIHW and the Steering Committee (see page xiii).  Both structures were necessary to 
ensure a national perspective regarding policy input from across all jurisdictions and 
technical expert advice on the survey design, content and methodology. 
 
A substantial amount of planning and research is needed in order to ensure that the 
significant investment of money required for surveys of this kind is realised in valuable 
and useful results that lead to better health strategies for the population, and that wide 




From the outset, a number of broad questions were considered.  
• What are the longer-term policy questions or issues that should form the basis of 
a national population health survey that includes physical and biochemical 
measures?  
• What health issues are important to consider now, and which are likely to 
emerge as significant for our nation over the next ten or twenty years?  
• What are the important gaps in information currently that a survey of this kind 
could help to remedy?  Can these be addressed in a single survey or is there a 
need for a program of periodic surveys? 
• Are there certain population groups that should be considered as a priority for 
inclusion? 
• What are the directions for future population health surveying and data 
collection nationally, and how does a national health measurement survey 
program fit within a longer-term view?   
 
These questions formed the basis of the developmental process that was undertaken 
and the Inter-Governmental Steering Committee and Reference Group met regularly 
from early 2000. This proposal is the result of their deliberations and of wider 
consultations within their jurisdictions. The Business Case documents the benefits of 
such a survey program for Australia, the proposed design, content and methodology, 
associated ethical issues and likely cost. If this proposal is supported, further 
developmental work will be required, including survey piloting and wider community 
and health industry consultation. 
 
The opportunity to invest in a national population health survey program that contains 
physical and biochemical measures will provide a firmer foundation for health policy 
development in Australia in the new century.  
 
1.3  Outline of the proposed Australian Health Measurement Survey 
program 
 
The proposed AHMS program has been developed as a program of cross-sectional 
surveys that include a component of physical and biochemical measurement, and will 
examine a range of disease outcomes and risks.  The broad aim of the program is the 
collection of population health information at a national level – specifically designed to 
assist in the development of health policy and service planning, to assess the degree of 
success of health promotion or illness prevention strategies and to contribute to a 
greater understanding of health and illness in Australia via research. 
 
The AHMS program will be nationally representative of people of different age, sex, 
geographic area and socioeconomic circumstances.  It will combine questionnaire 
responses and physical and biochemical measures (such as measurement of height and 
weight; analyses of samples of blood, urine, and saliva; and tests of function).  The 
program of surveys allows for the inclusion of a wider range of content areas than a 
single ‘stand-alone’ survey.  The design contains a 'core' of measures, which is repeated 
at each survey, with one or more modules on subjects of special interest undertaken 
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opportunistically.  This model has been implemented successfully in the UK and the 
USA.  
 
There are a number of national health policy areas that have been identified as 
important for inclusion in the AHMS program, such as chronic disease comorbidities, 
onset of risk factors in childhood, overweight and obesity, mental health, lack of 
physical activity and nutrition, in addition to cardiovascular disease and diabetes 
mellitus. The survey will provide national prevalence estimates for a range of chronic 
diseases and conditions across relevant age groups.  
 
Two frameworks, The National Health Performance Framework (devised by the National 
Health Performance Committee (NHPC 2001) and AHMAC endorsed) and Preventing 
Chronic Disease: A Strategic Framework, (devised by the National Public Health 
Partnership (NPHP) (2001) and AHMAC endorsed) provide a mechanism to ensure 
national data collection develops in a coordinated way to fill information gaps in 
Australia.  The AHMS program offers an important opportunity to collect information 
to fill some gaps highlighted by these frameworks.  
 
The AHMS program is recommended to commence in association with the NHS.  The 
first survey of the AHMS program would be conducted with the NHS in 2004/5, 
preceded by a dress rehearsal in 2003/4.  The AHMS is, in effect, in two parts.  The first 
of these comprises the subjective measures undertaken in the NHS.  The second 
includes the physical and biochemical measurement undertaken in the AHMS.  It is 
proposed that the survey be repeated after six years, with the possibility of more 
frequent (e.g. three yearly) surveys once the initial results have been analysed and their 
contribution to policy development, program planning and research assessed.   
 
The proposed objectives of the AHMS program are: 
 to determine the prevalence of selected disease outcomes and risk 
factors/determinants in the Australian population and selected population 
groups, as a basis for policy and strategy development; 
 to monitor trends in the prevalence of identified disease outcomes and risk 
factors/determinants in the Australian population and selected sub-population 
groups; 
 to examine the relationships among selected diseases and risk 
factors/determinants; and, 
 to validate self-report of selected risk factors/determinants using biological 
measures, in order to assess the validity of time trends in health indices obtained 
using self-report. 
 
Information from the surveys will be used: 
 to generate reliable evidence over time to be used for population health planning 
and the evaluation of several major disease prevention and control activities, 
including the National Health Priority Area (NHPA) strategies; 
 to examine the relationships among selected diseases and risk 
factors/determinants to assist in focusing research efforts and policy 
developments; 
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 to provide the infrastructure for “opportunistic” testing of issues of concern (for 
example, lead or other pollutants) that may arise in the future; and, 
 to validate the self-report measures that are collected in face-to-face health 
surveys and potentially provide weights for adjustment of those surveys. 
 
Future opportunities for consideration within the AHMS program exist for 
administrative data linkage to cancer and death registries, possible sample storage and 
for the inclusion of a longitudinal component to allow follow-up of some participants 
over time, all subject to participant consent. These issues have been considered for the 
initial AHMS, but require considerable community consultation and ethical debate, and 
have therefore been excluded from the proposed AHMS program at this time. 
 
1.3.1   Two examples of possible outputs from the survey program and their value to 
health policy and planning 
The content areas of each survey will determine the outputs derived from the proposed 
AHMS program. Two examples highlighting survey programs overseas serve to 
identify the potential benefits of having accurate, up-to-date information about the 
population’s health to underpin health policy and program development. 
 
Folate status in US childbearing women 
In 1992, the US Public Health Service recommended that women of childbearing age 
increase their consumption of the vitamin folic acid, to reduce the occurrence of spina 
bifida and other neural tube defects in their offspring. To this end, national efforts were 
implemented to increase awareness and encourage the use of dietary supplements 
containing folic acid prior to conception. In 1996, the U.S. Food and Drug 
Administration (FDA) authorised the addition of folic acid to enriched grain products, 
with compliance mandatory by 1998.  
 
To assess the success of the preventive strategy, the US Centers for Disease Control and 
Prevention compared serum and red blood cell folate concentrations for childbearing-
aged women who participated in the 1999 National Health and Nutrition Examination 
Survey (NHANES 1999), to the same measures in childbearing-aged women who 
participated in the Third National Health and Nutrition Examination Survey (NHANES 
III, 1988-1994). Results from the NHANES 1999, which was conducted after 
implementation of food fortification and educational efforts to increase folate 
consumption, showed that these public health actions had been effective in increasing 
folate status among U.S. women of childbearing age (MMWR 2000).  
 
One of the US national health objectives for 2010 is to increase the proportion of 
pregnancies begun with an optimum folic acid level among nonpregnant women aged 
15-44 years (Objective 16-6b). On the basis of the results of the NHANES 1999, this 
objective has been met. 
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Predicting likely demand for cholesterol-lowering drugs  
Pharmaceutical treatments for risk factors are a significant driving force in the 
Pharmaceutical Benefits Scheme budget growth, and current prevalence estimates 
would therefore be valuable for economic modelling of likely future demand.  
 
In Australia, for the period April 1999 to March 2000, serum lipid-reducing drugs 
contributed the greatest increase in cost of drugs to Government (up $ 106.7 million). 
Simvastatin was the top PBS drug by cost to Government at a cost of $196.1m. 
Atorvastatin and Pravastatin, also statin drugs, were the second and seventh highest, at 
costs of $163.7m and $58.5m respectively (DHAC 2000). 
 
However, the use of lipid-lowering agents (the ‘statins’) has demonstrated survival and 
other benefits in secondary and primary prevention of coronary heart disease in those 
people with substantial risk (NHMRC 1996; Hulley et al. 2000).  Information from the 
proposed AHMS program would give more accurate estimates of current prevalence of 
raised blood lipids across age groups to support economic modelling of future demand 
and cost-effectiveness of these medications.  
 
In the UK, national guidelines for the prescription of statins, for people who either have 
established cardiovascular disease or are at high risk of developing it, have been issued. 
Using data from the Health Survey for England 1999, researchers reported recent data 
that showed that there were high rates of raised blood lipids among English adults, but 
that only 1 in 50 adults were taking lipid-lowering drugs (Primatesta & Poulter 2000).  
This research suggested that a significant number of adults with elevated blood lipids 
were a possible target for cholesterol-reducing treatment in England, and provided the 
basis to determine the likely budgetary impact if the guidelines were followed more 
rigorously. 
 
1.4   Relevance of the AHMS program 
 
The development of the AHMS program will align Australia with the USA, the UK, a 
number of European and Asian countries, and New Zealand.  The proposed AHMS 
program underpins the national strategy for monitoring health trends and expectations, 
and for identifying and responding to disease problems as they emerge.  In particular, 
the AHMS program will provide physical and biochemical measures of health status in 
addition to subjective, self-reported health information.  This will provide significant 
information to underpin prevention and management of chronic conditions such as 
obesity, diabetes, hypertension, heart disease, and respiratory disease.  The 
relationships between physical and biochemical and subjective measures of health, and 
measures of health service utilisation, will also provide important insights into health 
awareness, expectation and access to services.  Surveys repeated over time will monitor 
trends in selected chronic disease risk factors and outcomes.  
 
The AHMS program has been designed to be policy relevant and to maximise related 
research and development opportunities for health researchers. The physical and 
biochemical measurements in this program of surveys have been developed to 
complement and enhance current population health information collected in Australia, 
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and particularly the NHS and the recent AusDiab.   These measures are crucial for the 
development and monitoring of services for conditions which have been responsible for 
at least two-thirds of the mortality gain in the last 30 years, and which still offer the 
greatest prospects for mortality gain in the future – especially the National Health 
Priority Areas of circulatory conditions and diabetes, but there are also implications for 
major cancers. 
 
The decision to link the AHMS program with the NHS will allow validation of the self-
reported data that is collected in the NHS.  Work with the ABS on the AHMS program 
development resulted in a skirmish being undertaken in November 2001 to assess 
initial elements of the recruitment process to AHMS.  Preliminary results indicate 
adequate response rates that are similar to surveys of this kind overseas.  Additional 
piloting is now required, including the taking of measures (Appendix C: AHMS 
Skirmish Report (ABS)).  
The survey program is strongly supported by the divisions of the Department of Health 
and Ageing (DoHA), the AIHW and the ABS.  The States and Territories have also 
indicated high-level support and interest, particularly in broad, policy relevant content 
coverage.  Strong support has also been received from the scientific Reference Group, 




2.   OVERSEAS AND AUSTRALIAN POPULATION HEALTH 
MEASUREMENT SURVEYS 
 
2.1   Experience in other countries  
Numerous countries such as Finland, Germany, India, the Netherlands, Denmark, 
Latvia, Greenland, Canada and Australia have conducted single national health 
measurement surveys.  The majority have focused on cardiovascular health and 
included measures of body dimensions, blood pressure and analyses of blood samples.   
However, other countries have now established, or are developing, ongoing programs 
of population health surveys using physical and biochemical measures.  The key design 
features of these programs are summarised in Table 2.1.  Of these, the programs in the 
US and the UK are the most sophisticated, and survey results and analyses have been 
highly valued for use by policy-makers and researchers.  Each conducts their survey on 
an annual, rolling basis and includes a wide range of physical and biochemical 
measures.  Both of these programs survey children, offer interview and measurement in 
respondents’ homes (or in mobile clinics), have a longitudinal component for follow-up 
of participants, some linkage to administrative data and store collected samples for 
further research.  Further details about these programs are contained in Appendix A. 
A number of international surveys across countries have been established.  The current 
WHO initiative, Stepwise Approach to Surveillance (STEPS) of non-communicable 
disease risk factors, uses standardised questions and measurement protocols at three 
levels of monitoring, depending on available resources across developing and more 
developed countries worldwide (Bonita et al. 2001).  
Many countries are now favouring the survey design developed for the UK Health 
Survey for England (HSE), which has a core content component (measured at every 
survey), and special interest modules (measured less frequently or opportunistically).  
The core content is designed to monitor general health, common risk factors and the 
socioeconomic determinants of health over time.  Special interest modules examine 
particular health-related questions on an occasional or rotating basis in order to 
examine certain issues in greater depth.  For example, HSE undertook special interest 
modules focusing on cardiovascular disease (1994 and 1998); asthma, accidents, and 
disability (1995); children and young people (1997); ethnic groups (1999); and older 
people, and social exclusion (2000) (National Statistics and Department of Health, UK 
2001).  The Scottish, New Zealand, and the US NHANES survey have also adopted this 
model (see Table 2.1). 
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the home 
Core measures:  Blood pressure, height, 
weight, body dimensions, analyses of blood 
and urine 
 
Measures on sub samples: include ECG, 
audiometry, balance testing, bioelectrical 
impedance, cardiovascular fitness, body 
composition, bone densitometry, dermatology 
exam, lower extremity disease exam, muscular 
strength testing, oral health, vision testing, TB 
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body dimensions 
 
Measures related to individual survey topics: 
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weight, body dimensions, lung function, blood 
analyses 
 
Measures related to individual survey topics: 
Cardiovascular disease (blood) 
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1 From 1999, each annual sample is representative of the population; previously the total multi-year survey was required to achieve a representative sample. 
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impedance, blood pressure, blood analyses 
 
Measures related to individual survey topics: 
Child nutrition (1st survey) 
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impedance, blood pressure, tests of physical 
and mental functioning, vision and hearing, 
oral and dental health, ECG, spirometry, 
Blood, saliva, urine, and faecal analyses 
 
n.a. 9 
n.a* = Details not available in English 
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2.2   Previous Australian experience  
Several national population based studies conducted in previous years in Australia 
have included the collection of physical and biochemical measurements.  The key 
features of these surveys are outlined in Tables 2.2 and 2.3.   
Many smaller surveys, usually focused on particular geographic areas or special 
populations of interest, have also included physical and biochemical measurements but 
only ‘national’ population based surveys are described below.  The National Heart 
Foundation’s Risk Factor Prevalence Study surveys of capital cities have been repeated 
over time.  Thus, these surveys provide a time series of data on cardiovascular health 
that could be built on by the AHMS program.  Many of these studies demonstrate that 
the taking of physical and biochemical measurements, including in children, is likely to 
be acceptable to the Australian community.   
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Table 2.2: National population health surveys using physical and biochemical 
measurement in Australia 
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3. DEVELOPMENTAL PROCESS UNDERTAKEN 
 
The last decade has seen the development of several survey programs 
overseas that include physical and biochemical measurement, and an 
increasing interest in Australia for establishing a similar, coordinated national 
program.  The first Australian proposal began as a single biochemical risk 
factor survey to repeat, and build on, the information obtained from the 1989 
National Heart Foundation survey (see Section 2.2 Previous Australian 
experience).   
The proposal has since developed to follow the model adopted by the UK and 
USA, that of a coordinated national program of periodic population health 
measurement surveys to cover a range of public health issues over time.  The 
development of the proposed AHMS program is described below. 
 
3.1   The proposal for a National Biochemical Risk Factor 
Survey 
In 1997, the AIHW held a national workshop of interested parties on the need 
for a biochemical risk factor survey for Australia and a decision was made to 
develop a proposal for the Australian Health Ministers Advisory Council 
(AHMAC).  A Steering Committee was established and the AIHW undertook 
the planning of the survey and proposal development.  The proposal detailed 
the need for a single national biochemical risk factor survey and identified a 
range of biologic measures that focused on cardiovascular disease, diabetes 
mellitus, communicable diseases and nutrition (priorities determined by 
invited participants at the initial workshop).  The proposal canvassed a range 
of issues including coverage of children less than 18 years, and of rural and 
remote communities; storage of collected sera for further research; and the 
linking of results to other AIHW and ABS collections.  Survey design issues, 
such as linkage to the NHS, were not determined at that stage.   
The proposal was endorsed by the National Public Health Partnership 
(NPHP) in February 1999 and forwarded to AHMAC in April 1999.  AHMAC 
referred the proposal back to the NPHP for advice on funding.  The NPHP 
commissioned the AIHW to prepare a business case that was presented to the 
National Public Health Information Working Group (NPHIWG) in September 
1999.  It identified that the single survey would cost at least $3 million.  The 
need for such a large investment led the (then) Commonwealth Department 
of Health and Aged Care (DHAC) and AIHW to agree to an additional 
process of planning and development.   
Following discussion at the DHAC Policy Forum on 20 September 1999, the 
Public Health Information Development Unit (PHIDU) was asked to provide 
further advice on survey development issues including the linking of the 
survey to the NHS.   
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In November 1999, the NPHP endorsed an approach that focused on:  
 developing a strong rationale and business case for the survey, with 
particular focus on policy implications, future information needs and cost; 
 planning the content, scope, design and methodology for the survey and 
involving researchers and other parties to assist with those matters;   
 engaging the attention and interest of policy makers across health 
portfolios in all jurisdictions, through a formal consultation process, in 
order to consider longer-term policy perspectives and implications, to 
identify other initiatives which could add value to the survey, and to 
determine support for such a survey; and, 
 engaging consumer groups and the wider community in the survey 
planning to ensure that their interests and concerns are addressed and to 
determine their support for such a survey. 
 
3.2   The development of the AHMS program 
Following endorsement of the terms of reference, a new Inter-Governmental 
Steering Committee was established to develop the proposal further (see page 
xi for the Committee membership).  The Committee determined that a 
program rather than a single survey was required, in order to provide the 
breadth of necessary health information that was currently unavailable.  The 
Committee proposed the name, the Australian Health Measurement Survey 
program.  
A consultative process was undertaken with Commonwealth, State and 
Territory jurisdictions to ascertain their policy priorities in order to frame 
potential program content in a policy context.  A number of national health 
policy areas were identified as important, including chronic disease 
comorbidities, onset of disease risk factors in childhood, overweight and 
obesity, mental health, lack of physical activity and nutrition, in addition to 
cardiovascular disease and diabetes mellitus.  There was interest across 
jurisdictions for the AHMS program to provide national prevalence estimates 
for a range of chronic diseases and conditions across relevant age groups.  
Two frameworks, The National Health Performance Framework (devised by the 
National Health Performance Committee (NHPC 2001) and AHMAC 
endorsed) and Preventing Chronic Disease: A Strategic Framework, (devised by 
the National Public Health Partnership (NPHP 2001) and AHMAC endorsed) 
provide a mechanism to ensure national data collection develops in a 
coordinated way to fill information gaps in Australia.  These frameworks 
were used to determine the scope that was required of the AHMS program.  
After several iterations, a content framework was developed based on these 
frameworks (see Appendix B: A framework for considering the content of the 
AHMS program).  An expert technical Reference Group was convened to 
provide advice on the best measures for the content areas contained in the 
framework (see page xiii for the Reference Group membership).  Other 
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experts were approached on the advice of the Reference Group, and a 
separate teleconference was organised with members of the Communicable 
Diseases Network of Australia and New Zealand, to discuss information 
needs and content issues in the area of communicable diseases.  
The proposed AHMS program was developed as a program of cross-sectional 
surveys that include a component of physical and biochemical measurement, 
and that will examine a range of disease outcomes and risks.  It will be 
nationally representative of people of different ages, sex, geographic area and 
socioeconomic circumstances.  It will combine questionnaire answers and 
physical and biochemical measures (such as measurement of height and 
weight, analyses of samples of blood, urine, and/or saliva and tests of 
function).  
The Steering Committee explored a range of design options around the 
concepts of a ‘stand alone’ survey or one that could be linked with the NHS. 
After a number of discussions with the ABS, it was agreed that linking the 
NHS and AHMS would be the most constructive way forward.  Advice was 
also sought from the ABS to address specific design issues raised by the 
Steering Committee.   
 
3.3   Linkage to the ABS National Health Survey 
Three important issues were identified by the ABS that impinge on a linked 
design: 
 the ABS advised that the Australian Bureau of Statistics Act 1975 
prohibits their staff from collecting physical and biochemical measures; 
so an external agency or agencies would be needed to conduct the 
AHMS component of a linked survey;   
 the ABS is prohibited by this Act from releasing the names or 
addresses of respondents agreeing to participate in the AHMS to an 
external agency; thus, the respondent would need to contact the 
external agency directly; and,  
 if an external agency knew the identities of the examined respondents, 
confidentialised unit record files (CURFs) for the entire survey could 
not be released by the ABS, because the external agency could 
potentially identify the files by matching them to their results’ records.   
In relation to the issues detailed above, the ABS proposed a range of options 
under which the NHS could be associated with the AHMS program.  The 
following approach was selected.  
At the conclusion of the NHS interview, respondents will be asked if they 
would be willing to consent to a nurse visiting their home for the AHMS 
during which a range of measures would be taken.  The ABS interviewer 
would then provide the respondents with a consent form together with a 
reply paid envelope addressed to the external AHMS agency.  If signed at the 
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time, the ABS interviewer would offer to accept the form for passing to the 
external agency.  Respondents who do not consent at the time will be able to 
mail their consent forms to the AHMS agency.  The ABS will also make 
further contact with respondents who have accepted the consent form but 
want more time to consider their decision, to encourage them to participate. 
The AHMS agency will then contact the respondents to arrange a time for a 
nurse to visit them in their home to take the measurements.   
The results of the tests will be sent back to the ABS to be matched to the NHS 
interview.  As a list of names has been held by the external agency, no CURF 
will be able to be released.  Data access arrangements are outlined in Section 
7.1 Data access.   
The Commonwealth, States and Territories agreed with the proposed method 
detailed above, and it was on this basis that the ABS undertook the skirmish. 
 
3.4   Skirmish results and proposed pilot test 
The AHMS skirmish conducted by the ABS (November/December 2001, 
simultaneously in NSW and SA) tested levels of recruitment to the AHMS 
program.  Respondents were asked whether they would agree to being 
contacted to make an appointment for the series of samples (blood, saliva and 
urine) and physical measurements (height, weight and waist circumference) 
to be taken.  Intent to allow the measurements to be taken was tested, rather 
than willingness to sign a consent form.  No consent forms were produced for 
signing, and no actual measurements were taken.   
A sample size of 677 dwellings in NSW and SA was selected.  Interviewers 
randomly selected one (usual resident) adult aged 18 years and over (using 
the next birthday method) per household for the NHS interview and this 
person was also interviewed for the AHMS.  Respondents who were parents 
were also asked whether they would agree to have their children involved in 
the AHMS, although this was not followed through with the children 
themselves. 
The NHS questionnaire was shortened so that the full skirmish interview 
averaged 45 minutes per household.  After asking the NHS questions, 
interviewers introduced the AHMS.  Following the introduction, respondents 
were asked whether they would agree to having another organisation contact 
them to arrange an appointment to have the measurements and samples 
taken.  After this, respondents were informed that they had been involved in 
a test of respondent reaction to such a survey and that the AHMS was not 
being conducted at this point in time.  They were then asked a further series 
of questions on their reasons for agreeing/not agreeing to participate.  Those 
who had agreed were asked their preference of location for tests (at home or 
at a clinic).  Those who had not agreed were asked whether there were 
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conditions that would change their decision regarding agreement (such as 
removal of certain tests, change of location).  
3.4.1 Response rate 
The total NHS response rate for the skirmish was 68.1% (fully responding) 
and 59.0% of these agreed to being contacted for the AHMS measurements.  
This response rate was achieved without any of the usual ABS survey follow 
up protocols for refusals, or employment of interpreters where language 
difficulties existed (fully responding response rates achieved in recent NHS’s 
have been well over 90% with such follow up). 
Generally, interviewers reported that respondents were receptive to the 
AHMS, and they felt that the number of persons agreeing could be increased 
by a variety of actions (such as providing more information on how results 
would benefit the general public, providing a copy of test results to 
participants, and following up those who thought they were ‘too healthy’, 
‘too old’ or were currently having tests regularly).  On the basis of these 
potential follow up actions, ABS advised that the final response rate for the 
AHMS could be increased to 75% of those people fully responding to the 
NHS.  However, overseas experience suggests that a drop off rate of about 
16% may be expected prior to respondents actually seeing a nurse. 
3.4.2 Reasons for agreement and non-agreement 
The major reasons given by those who agreed to be contacted for the AHMS 
(256 persons) were ‘I wanted to contribute to a good cause’ (43%); ‘Assume I 
will get results/interested to see my results’ (41%); and ‘will help understand 
risk factors’ (41%). 
The major reasons given by those who did not agree (178 persons) were 
‘already having these tests/would prefer to go to own doctor’ (22%); ‘no 
time/too busy’ (31%); and ‘types of tests/physical nature of tests’ (21%). 
A total of 41% of those who did not initially agree, would agree to have some 
measurements or samples taken.  (See Appendix C: AHMS Skirmish Report 
(ABS) for more details.) 
3.4.3 Full pilot test recommended  
Following the skirmish, the ABS recommended that a full pilot test be run to 
provide more information on drop off rates and to clarify response rates 
achievable from initial agreement to consent (at the nurse interview) and the 
actual collection of measurements and samples.  The pilot test would also 
ascertain the number of children (in addition to their parents) who give their 
agreement (not tested in the skirmish). 
If results of the full pilot test were favourable, the agency undertaking the 
contract to conduct the first AHMS, would then undertake a dress rehearsal 
prior to the conduct of the survey proper. 
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3.5   Issues considered but not included in the initial AHMS 
A range of design issues were considered but were rejected by the Steering 
Committee for inclusion as part of the initial survey, and these are detailed 
below. 
3.5.1 Sample storage for future research purposes 
Storage of collected blood samples for possible later use (such as further 
analyses) was extensively discussed.  Samples are successfully stored in both 
the long running US and UK health measurement surveys (NHANES and the 
Health Survey for England).  However, the need to obtain open-ended 
consents (to allow for analyses not known at the time of obtaining consent) 
from participants recruited to AHMS was regarded as a likely impediment to 
achieving the necessary high response rates for the survey.  The Steering 
Committee also felt that there were significant ethical, legal and privacy 
issues regarding the storage of samples that required further consideration 
and consultation.  The likely high cost of storage was also identified. 
3.5.2 Administrative data linkage 
The linkage of AHMS respondents’ data to administrative collections (such as 
cancer and deaths registries) with consent was considered as a potential 
design element.  Comparable overseas surveys have linked respondents’ data 
to administrative and other data collections.  However, the ABS is not 
currently in a position to undertake administrative data linkage for the NHS, 
and any decision regarding data linkage within the AHMS was therefore 
delayed pending the outcome of the ABS’ review of their position. 
3.5.3 Longitudinal follow-up component 
The follow-up of some participants over time in subsequent surveys, adding a 
longitudinal component to the cross-sectional AHMS (and NHS), was another 
design element considered.  Longitudinal follow-up has been successfully 
undertaken in the US for instance, in the NHANES I Epidemiologic Followup 
Study, designed to provide data on mortality, morbidity, and hospital 
utilisation as well as changes in risk factors, functional limitation, and 
institutionalisation.  However, it was decided not to include this element in 
the AHMS program design until evidence of the value of the survey becomes 
clear.  
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3.5.4 Indigenous populations 
The conduct of the AHMS on a sub sample of respondents to the 2004/5 NHS 
means that the 1.1% of the Australian population (which includes 17.8% of all 
Indigenous people) who live in the sparsely settled areas of Australia will be 
excluded.  Due to current NHS sample size restrictions, it may not be possible 
to produce reliable estimates for Indigenous people for (at least) the first 
survey in the AHMS program. 
Over-sampling of Indigenous populations and inclusion of the sparsely 
settled areas are to be considered in the AHMS program, depending on ABS 
advice on methods to improve coverage in these areas and consultation with 
Indigenous communities.  The potential for individual surveys in the 
associated NHS and AHMS program to over-sample in Indigenous 





4.  SURVEY CONTENT 
 
The proposed AHMS survey design will allow both physical and biochemical 
measurements and subjective (self-reported) health information to be 
collected from the same respondents.  In the NHS, respondents will be 
interviewed in their homes on a range of health subjects.  At the conclusion of 
the NHS interview, respondents will be asked if they would be willing to 
consent to a nurse visiting their home for the AHMS during which a range of 
measures would be taken.  The ABS interviewer would then provide the 
respondents with a consent form together with a reply paid envelope 
addressed to the external AHMS agency.  If signed at the time, the ABS 
interviewer would offer to accept the form for passing to the external agency.  
Respondents who do not consent at the time will be able to mail their consent 
forms to the AHMS agency.  The ABS will also make further contact with 
respondents who have accepted the consent form but want more time to 
consider their decision, to encourage them to participate. The AHMS agency 
will then contact the respondents to arrange a time for a nurse to visit them in 
their home to take the measurements.  (See Section 5.3 - The AHMS program 
design, for more detail.) 
Thus the physical and biochemical measures from the AHMS will be 
supplemented by the subjective information collected through self-report by 
respondents to the NHS interview.  These include the prevalence of selected 
disease conditions and associated risk factors (such as tobacco exposure, 
physical activity, food and supplement intake, alcohol intake), psychosocial 
factors, health management, mental health, socioeconomic status and 
demographic information.   
Core content will, over time, allow for the monitoring of the Australian 
population with respect to: 
 body dimensions; 
 selected diseases, risk factors and socioeconomic determinants of 
health; 
 relationships between selected diseases, risk factors and determinants 
(for example, the relationship between cardiovascular disease, smoking 
and socioeconomic status); 
 the progression of risk over the life course; 
 the contribution of risk factors and socioeconomic determinants of 
health to the overall disease burden. 
Once a commitment to link the NHS and the AHMS is in place, and if funding 
for the AHMS is confirmed, the content of the NHS and AHMS will need to 
be aligned, in order that the overall usefulness of data gained from each is 
maximised for policy and research purposes.  Thus, both components are 
necessary to answer the desired policy questions and to enhance the 
usefulness of the NHS when it is not run in conjunction with an AHMS.   
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The content of the NHS should ensure the necessary self-reported data is 
present to maximise the validation possibilities flowing from the measured 
prevalence of selected diseases and associated risk factors.  It will also be 
necessary to confirm that the best information on the non-health determinants 
of health (such as socioeconomic status) is available to identify any 
associations with the health data. 
Discussions are continuing with the ABS regarding the initial AHMS content 
of the NHS in 2004/5.  While there are many agencies with an interest in the 
outputs from the NHS, the DoHA, as a significant contributor to the funding 
of the NHS should also be recognised as a stakeholder with a major interest in 
its content.  Suggested NHS content to make the best use of the AHMS data is 
contained in Table D.2 in Appendix D (Proposed content for the AHMS 
program).  
It is proposed that the AHMS program have two content components: a core 
set of physical and biochemical measures at every AHMS, and opportunistic 
special interest modules.  These are described in detail below, in Section 4.3 – 
Core set of physical and biochemical measures, and in Section 4.4 – Special 
interest modules. 
4.1 Selection criteria to determine AHMS program content 
The Steering Committee used the following criteria to select the broad content 
areas that should be included in the AHMS program. The content areas 
should: 
 be issues of national public health importance and reflect government 
health objectives; 
 address problems that could be changed through public policy and 
strategy initiatives; and, 
 have reliable, replicable and valid measures that are easy to administer 
and that link with other areas for which physical and biochemical 
measures are required. 
 
4.2   Development of a framework for the AHMS program 
content 
A consultation process was held with DoHA, AIHW and the State and 
Territory jurisdictions to elicit their policy priorities.  This information was 
incorporated into a comprehensive framework that was based upon The 
National Health Performance Framework (devised by the National Health 
Performance Committee (NHPC 2001) and AHMAC endorsed) and Preventing 
Chronic Disease: A Strategic Framework, (devised by the National Public Health 
Partnership (NPHP 2001) and AHMAC endorsed).  This framework is in 
Appendix B – A framework for considering the content of the AHMS 
program. 
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The AHMS framework included a range of health conditions that are current 
National Health Priority Areas, and outlines: 
 their public health importance, priority and estimated burden;  
 their risk factors and determinants; 
 related government policy and strategy initiatives;  
 relevant physical and biochemical measures to determine prevalence; 
and,  
 potential uses of the information gained from the physical and 
biochemical measures. 
The framework summarises the three rounds of consultation undertaken to 
date.  All measures included in the framework met the selection criteria 
outlined in Section 4.1.  The risk factors and determinants common to a range 
of selected diseases form the basis of the core of measures for the AHMS 
program (see Section 4.3 - Core set of measures).   
 
4.3 Core set of physical and biochemical measurements 
It is proposed that a core set of measures be collected in every survey in order 
to provide a consistent picture of common diseases, their risk factors and 
socioeconomic determinants of health over time.  This approach is used in the 
Health Survey for England, which includes in its core content the measures of 
height, weight, body dimensions and blood pressure, as well as subjective 
measures of general health, risk factors and socioeconomic status gained 
through interview.  In Australia, the subjective measures would be collected 
by the NHS. 
The core set of measures for the first AHMS is proposed as:   
 physical measurements: 
o height 
o weight 
o abdominal circumference  
o blood pressure 
o lung function tests: spirometry. 
 
 biochemical measurements:  
o analyses of blood: serum lipids (cholesterol, LDL, triglycerides, 
HDL); homocysteine, red cell folate and Vitamin B12; glucose; 
glycosylated haemoglobin (HbA1c); and insulin; 
o analyses of saliva: cotinine 
o analyses of urine: dipstick test urine, and spot urine for 
albumin/creatinine ratio. 
 
The Steering Committee has determined that most of the blood samples need 
to be taken after a period of fasting (for twelve hours).  This will allow 
comparison with the data from the National Heart Foundation’s and other 
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surveys (which used fasting samples) to provide time trends.  The inclusion of 
a fasting requirement for participants has implications for the survey design, 
response rates and survey costing.  The impact of fasting on response rates 
should be piloted in the ABS pilot test of the first AHMS. 
The following table (Table 4.1) identifies the proposed core measures 
(indicated by ) for the first and subsequent surveys.  Potential respondent 
age ranges for each measure are also shown. 
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Table 4.1:  Agreed physical and biochemical measures, by age of 
respondent, for the first AHMS 
 Age of respondent (in years) 
 2-11 12-14 15-19 20-29 30-64 65-74 
Agreed physical and biochemical measures 
Physical measurements:       
Height        
Weight        
Abdominal circumference       
Blood pressure        
Lung function - spirometry  7+      
Biochemical measures: blood analyses       
Serum lipid levels: (cholesterol, LDL, 
triglycerides (fasting), HDL (fasting)) 
      
Homocysteine (fasting)        
Red cell folate, Vitamin B12 (fasting)       
Glucose (fasting)       
Glycosylated haemoglobin (HbA1c)       
Insulin (fasting)        
Biochemical measures: saliva analyses       
Cotinine (tobacco exposure)  4+      
Biochemical measures: urine analyses       
Dipstick test urine       
Spot urine for albumin/creatinine ratio       
Note: proposed core measures shown as  
The following measures (not shown in Table 4.1) were considered by the 
Steering Committee, but excluded from the first AHMS at the present time:  
 Biochemical measures from analyses of blood:  
 C-reactive protein (measure of inflammation); 
 Oral glucose tolerance test  (OGTT) (proposed for a sub-sample; related 
to diabetes);  
 Serum creatinine (related to renal disease);  
 Measures of fruit and vegetable intake (carotenoids (lutein, 
cryptoxanthin, lycopene, beta carotene); measures related to certain 
cancers and nutrition generally). 
 Biochemical measures from analyses of saliva: 
 Cortisol (measure of ongoing psychosocial stress).  
All the measures proposed (those that have been agreed and those that were 
discussed but excluded) are shown in Table D.1 in Appendix D.  The 
relevance of each measure to the identified policy area of interest is also listed 
(for example, cardiovascular disease, diabetes, renal disease, etc.).   
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4.3.1 Relevance of the measures selected 
a)  Height, weight, body dimensions 
Measures of height and weight are required to calculate the Body Mass Index 
(BMI), which is used to identify cut-offs for classifying proportions of the 
population as underweight, overweight, or obese. Body dimensions, such as 
abdominal circumference, also reflect nutritional status and are used to assess 
distribution of body fat. 
Being overweight  (either excess weight or obesity) is one of the most 
common factors influencing the development of high blood pressure and 
diabetes. These conditions, in turn, are two important risk factors for heart 
disease and stroke.  
Evaluation of body measurements will also provide nationally representative 
data on selected body measurements, overall and for age and gender 
categories; provide estimates of the prevalence of overweight and obesity; 
provide data to study the association between body measures and body 
composition, other health conditions and risk factors such as cardiovascular 
disease, diabetes, hypertension, and physical activity and dietary patterns; 
and monitor physical growth and development in children. 
b) Blood pressure 
Raised blood pressure is an important risk factor for cardiovascular disease, 
(both coronary heart disease and stroke). The risk of cardiovascular disease 
increases as the level of blood pressure increases. Although less is known 
about the distribution of blood pressure in children than in adults, evidence 
supports the idea that the roots of essential hypertension extend back to early 
adulthood (Lauer & Clarke 1989). Blood pressure is known to have a stronger 
relationship with age, height and weight in children than in adults (Chen et 
al. 1995; Clarke et al. 1986; Kaas Ibsen 1985). 
 
c) Lung function tests 
Spirometry measures lung function and, by using predictive equations (based 
on reference populations, for age, height, and gender), provides a measure of 
difference between the measured and expected lung function.  Cross-sectional 
estimates of spirometric function allow declines in function to be inferred and 
are predictive, in a population, of systematic airflow obstruction and 
premature mortality (G Marks, personal communication).  Tests of lung 
function using spirometry can be made on children from the age of 7 years on, 
to identify the presence of diseases that interfere with the growth of lung 
function. Tests of airways resistance (in development 2002, likely to be 
useable in population surveys by 2004) potentially extend the ability to test 
lung function in populations from 2 years old, and would be preferred to 
spirometry for children aged between 2 and 7 years (G Marks, personal 
communication).  A challenge test for asthma is not recommended for 
inclusion in a survey conducted in the home environment. 
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d) Blood lipids 
High blood cholesterol is linked with the development and progression of 
atherosclerosis and subsequent coronary heart disease (Law et al. 1994). Blood 
lipid components contribute disease risk in specific ways. Elevated levels of 
total blood cholesterol, low density lipoprotein (LDL) cholesterol, and 
triglycerides increase cardiovascular disease risk, while higher levels of high 
density lipoprotein (HDL) cholesterol exert a protective, risk lowering effect.  
e)  Homocysteine levels in the blood 
Blood homocysteine levels are an important, independent risk factor for 
clinical atherosclerosis and venous thrombosis (Malinow 1999). Elevations in 
serum homocysteine are associated with early coronary artery disease and 
stroke and with venous thromboembolic disease. It is thought to add to the 
risk of cardiovascular disease by provoking both atherosclerosis and clot 
formation.  
 
Vitamin B12 and folate are essential cofactors required for homocysteine 
metabolism and are important determinants of homocysteine levels in the 
blood. All are affected by food intake. As blood levels of homocysteine are 
dependent on folate and vitamin B12, these need to be measured 
simultaneously. 
f) Folate and Vitamin B12 levels in the blood 
Folate plays an important role in the prevention of neural tube defects among 
women of childbearing age.  Because of the interaction of vitamin B12 with 
folate metabolism, the nutritional status of both the factors needs to be 
assessed simultaneously.  
g)  Glucose, glycosylated haemoglobin and insulin levels in the blood 
The accurate diagnosis of diabetes requires clinical tests, such as the two-hour 
oral glucose tolerance test (OGTT) and the evaluation of related symptoms in 
a clinical examination, which are beyond the scope of this survey.  
Nonetheless, information on the prevalence of diabetes markers and risk 
factors will be collected. Specifically, the diabetes measurements in the survey 
will provide population data to determine national estimates of the 
prevalence of diabetes markers and risk factors in people with diagnosed and 
undiagnosed diabetes. There are also several common risk factors and 
indicators associated with both diabetes and cardiovascular disease including 
overweight and obesity, high blood pressure and high blood lipids.  Many of 
the anthropometric and blood measurements described above for nutrition 
and cardiovascular disease are also relevant to diabetes. 
 
Glycosylated haemoglobin (HbA1c) is an index of average blood glucose level 
for the previous 2 to 3 months and is used to monitor blood sugar control in 
diabetic people.  Although not as sensitive as OGTT in the diagnosis of 
diabetes, HbA1c is a practical marker of diabetes risk in population-based 
surveys.  It appears to be a marker of the increased risk of developing 
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atherosclerosis, myocardial infarction, strokes, cataracts and loss of the 
elasticity of arteries, joints and lungs.  It is also associated with psychological 
measures of stress in a number of studies, both in non- and in diabetic people 
(Kelly, Hertzman & Daniels 1997).  Fasting blood glucose is also used to 
assess diabetes and its inclusion in the survey will help estimate the 
prevalence of glycaemia in the sampled population.  Serum insulin is a 
measure of insulin resistance. 
h)  Salivary cotinine 
Cotinine is a metabolite of nicotine.  It is one of several biological markers that 
are indicators of smoking (others include carbon monoxide and thiocyanate), 
and is generally considered the most useful.  The measurement of cotinine 
levels provides an objective crosscheck on self-reports of smoking behaviour, 
which are known not always to be accurate.  Inaccuracies in reporting arise in 
part from difficulties informants may experience in providing quantitative 
summaries of variable behaviour patterns, but in some cases arise from a 
desire to conceal the truth from other people, such as other household 
members who may be present during the interview. Limitations on the ability 
of self-report to provide accurate quantitative responses are particularly 
marked in relation to exposure to other people's smoking (passive smoking).  
 
Salivary cotinine will be used to assess the prevalence of exposure to tobacco 
smoke (both passive and active) and to validate self-reported exposure.  
i) Dipstick urine and spot urine analysis for albumin/creatinine ratio 
Dipstick tests of urine and spot urine analyses for albumin/creatinine ratio 
are used to assess the prevalence of early renal impairment, through the 
detection of microalbuminuria, the earliest stage of renal disease and an 
independent risk factor for cardiovascular events (Borch-Johnsen et al. 1999, 
Lydakis & Lip 1998), and predictive of progression to renal failure in both 
diabetic and non-diabetic renal disease (Rossing et al. 1993, Ruggenenti et al. 
1998a).  Albumin/creatinine ratio in spot morning urine samples is a precise 
indicator of proteinuria and a simple and inexpensive procedure in 
establishing severity of renal disease and prognosis (Ruggenenti et al. 1998b).   
 
4.4   Special interest modules 
As described, a modular survey design is proposed for the AHMS program, 
with a core set of measures (maintained over time for trend comparisons), 
together with one or more modules on subjects of special interest.   
Special interest modules would be undertaken opportunistically in individual 
surveys (once only, occasionally, or on a rotating basis) in order to examine 
particular health issues in greater depth.  Special interest modules can be 
focused on disease outcomes, risk factors, and age or population groups. 
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Special interest modules used by the Health Survey for England have 
included cardiovascular disease (1994 and 1998); asthma, accidents, disability 
(1995); children and young people (1997); ethnic groups (1999); older people 
and social exclusion (2000). Modules planned from 2001 to 2006 are disability, 
asthma, accidents, physical activity, eating habits, oral health, cardiovascular 
disease, and social exclusion for various age and ethnic groups (Department 
of Health, UK 2000).   
Special interest modules proposed for AHMS were: 
 the Metabolic Syndrome or Syndrome X2 (proposed for the first 
survey);  
 nutrition (proposed for the second survey). 
Since the original decision for a modular design, the number of items added 
to the core set of measures for the first survey in the AHMS program has 
increased to the extent that there is currently little opportunity to include any 
additional special interest measures in this survey.  However, the possibility 
may arise to include a short questionnaire module on a topic of interest as 
part of the rapport-building process used by the nurse (see Section 5.3.4).   
                                                 
2  The World Health Organization has classified a specific clustering of risk factors as the 
Metabolic Syndrome (Syndrome X). Insulin resistance–-either impaired glucose tolerance, 
impaired fasting glucose or diabetes–-is thought to be the underlying defect in this syndrome. 
In addition to insulin resistance, a person with the Metabolic Syndrome will usually have one 
or more of the following risk factors: high cholesterol, high blood pressure and central 
obesity. The syndrome vastly increases a person’s risk of developing type 2 diabetes or 






5.  SURVEY DESIGN  
 
5.1 Overview 
As noted above, it is proposed that the AHMS program be conducted in 
conjunction with the NHS.  The NHS is conducted approximately every three 
years (2001, completed; 2004/5, 2007/8 and 2011/12, proposed).  It is 
proposed initially that the AHMS be conducted every six years.   
 
5.2  Survey coverage  
The NHS approaches a sample of the Australian population living in private 
dwellings (as determined by the ABS’s multi-stage stratified probability 
sampling design).  One adult, one child/adolescent aged 7 to 17 years and all 
infants and children aged below 7 years are currently selected in each 
household in the NHS.  The AHMS will take a sub-sample of this population 
(see Section 5.4 - Sample design and selection, below). 
It should be noted that the NHS does not include the homeless or those living 
in institutions (e.g. hospitals, prisons and nursing homes).  These groups may 
have poorer health than those in the proposed sample and this will need to be 
considered when interpreting the AHMS results. 
In addition, the NHS does not include the 1.1% of the Australian population 
who live in the sparsely settled areas of Australia.  These areas are excluded 
because of the sparsely settled nature of their population and the costs and 
other difficulties associated with surveying in such areas.  Their exclusion is 
of particular importance, as 17.8% of all Indigenous people live in these areas, 
compared with only 1% of the non-Indigenous population.  It is not currently 
possible to produce reliable estimates from the NHS for Indigenous people, a 
group that has the poorest health in Australia: their exclusion will also need 
to be considered when interpreting the AHMS results. 
The ABS has been consulting with Indigenous groups and agencies, to 
ascertain ways to improve the coverage of data in the NHS from the sparsely 
settled areas.  It is proposed that the 2004/5 NHS include a larger sample of 
the Indigenous population: in addition, the method of conduct of household 
interviews and the survey content is to be reviewed to ensure their relevance 
to Indigenous people in these remote areas.  Inclusion of the sparsely settled 
areas, with their Indigenous population, in the AHMS program will be 
considered in relation to subsequent surveys, depending on the outcomes of 
the ABS processes described above. 
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5.3 The AHMS program design 
 
5.3.1  Recruitment to the AHMS 
It is proposed that, at the conclusion of the NHS interview, respondents aged 
less than 75 years be asked if they would be willing to consent to a nurse 
visiting their home for the AHMS, during which a range of physical measures 
would be taken.  The ABS interviewer would then provide the respondents 
with a consent form together with a reply paid envelope addressed to the 
external AHMS agency.  If signed at the time, the ABS interviewer would 
offer to accept the form for passing to the external agency.  Respondents who 
do not consent at the time will be able to mail their consent forms to the 
AHMS agency.  The ABS will also make further contact with respondents 
who have accepted the consent form but want more time to consider their 
decision, to encourage them to participate. The AHMS agency will then 
contact the respondents to arrange a time for a nurse to visit them in their 
home to take the measurements.  
5.3.2  Nurse visit to the home 
The nurse will contact respondents to the NHS, who agree to a nurse visit, 
and a time made to visit the respondent at their home.  At that visit, the nurse 
will seek consent to take a range of physical and biochemical measurements.  
Where fasting is required for blood analyses, appropriate information will be 
supplied and arrangements made for the nurse to call back and take the 
measurements.   
International survey experience suggests a nurse visit to the home is the best 
way to maximise response, and home visits and mobile clinics have now been 
incorporated in models in other countries (see Section 2.1, Experience in other 
countries).  Results from the skirmish undertaken by the ABS in November 
2001 also indicate a preference for a nurse to visit the home.  Home visits are 
particularly feasible for the first survey of the AHMS program because the 
measures proposed require simple, portable equipment.  In subsequent 
surveys, when more complex measures requiring additional equipment might 
be included, the AHMS could be conducted in a venue outside of the home.   
5.3.3  Population covered and consent 
It is proposed that the population to be covered in the AHMS be those aged 
from 2 to 74 years from the NHS interview who agree to participate in the 
measurement phase.  Information will be obtained directly from those aged 
12 to 74 years.  Information about children aged from 2 to 11 years will be 
obtained from a parent, with the child present.   
Consent for the collection of physical and biochemical measures will be 
obtained from all respondents 18 years and over and from the parents of 
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those under 18 years.  Assent, as distinct from parental consent, will be 
obtained from those under 18 years before any measurements are taken.   
For the physical and biochemical measures, it is proposed that: 
 height and weight will be taken from those aged 2 to 74 years; 
 abdominal circumference will be taken from those aged 2 to 74 years; 
 lung function tests will be performed on those aged 7 years and over; 
 a blood sample will be collected from those aged 18 years and over;  
 a blood sample (by venepuncture after the application of anaesthetic 
cream) will be taken from those aged 12 to 17 years;  
 a saliva sample for cotinine assay will be collected from those aged 4 
years and over; and 
 a urine sample will be collected from those aged 12 years and over. 
 
5.3.4  Estimated time for taking measurements 
The Health Survey for England, where it takes a nurse between 3 to 10 
minutes in respondents under 4 years, and up to 40 minutes in respondents 
over 65 years, provides the most reliable information available regarding the 
time required to take the measurements.  The times include (depending on 
age) the taking of blood, saliva, blood pressure, lung function tests and waist, 
hip and demi-span measures.   
The times exclude: 
 the measurement of height and weight, because, in the HSE, the 
interviewer takes them; 
 the time necessary to ensure that the person identified in the NHS 
interview (and consenting to the nurse visit) is, in fact, the person from 
whom the nurse is to take the measures; and 
 the time for the nurse to establish rapport with the respondent. 
With regard to the last point, the ABS have advised that, in undertaking the 
National Nutrition Survey in 1995, time was needed to establish rapport with 
the respondent before taking the measurements (in that case, measures of 
height, weight, blood pressure and waist and hip circumference for 
participants aged 16 years and over). The ABS advice indicates that it would 
be appropriate to do this by asking a number of straightforward, but related, 
questions for up to 10 minutes. These could include the socioeconomic status 
questions identified in the policy consultations for the AHMS program, but 
not currently contained in the NHS interview, or a short module on a topic of 
interest such as nutrition. It is important to note, however, that it is not 
intended that the AHMS incorporate a lengthy questionnaire. 
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If children or others are offered anaesthetic cream for the taking of blood 
samples, then these times would increase, as the cream needs to be applied at 
least an hour before venepuncture, to be effective.  Should this approach be 
adopted, there would be more time in which to ask a range of questions 
specific to children and families, while waiting for the cream to work. 
 
5.4   Sample design and selection 
5.4.1 Overview 
There are a number of considerations in determining the size of the sample.  
Aside from cost, which is discussed in Section 9, the most important of these 
is the expected prevalence in the population of the health conditions for 
which measurements are being collected in the AHMS program.  Examples 
are given below of the number of people for whom measurements would be 
needed in order to determine the prevalence of certain conditions.   
The AHMS program is proposed as a national survey, with the availability of 
estimates at the State level being purely opportunistic (and related to the 
State’s size and, therefore, share of the national sample).  However, there is 
considerable interest in the extent to which estimates might be available at a 
regional level, whether by capital cities and the rest of Australia, or by some 
other categorisation, such as the Accessibility/Remoteness Index of Australia 
(ARIA)3.  In the initial survey, it is unlikely that data would be available for 
more than the first three of the five remoteness classes, and any ‘residual’ 
results for the combination of the two remote classes would be statistically 
unreliable.  Should it be possible to include in a later survey a larger sample of 
the population of the sparsely settled areas of Australia (as discussed above), 
the possibility of producing estimates for some topics and measurements 
would be increased. Ultimately, the final sample design will be determined in 
conjunction with the ABS.  
5.4.2 Sample size considerations 
As noted above, the expected prevalence of the health conditions for which 
measurements are being undertaken in the AHMS program will determine 
the size of the sample.  The following examples show the number of people 
for whom measurements would be needed in order to determine the 
prevalence of high total cholesterol, and depressed cholesterol levels, in the 
population.  The examples are summarised in Table 5.1. 
                                                 
3 The ARIA Index, comprising five remoteness classes, was developed for the Commonwealth 
Department of Health and Aged Care (DHAC 1999) to compare information about 
populations based on their access, by road, to service centres (towns) of various sizes.  The 
ABS has developed a modified version (ARIA+) for use in the NHS and other collections.  
The first three classes cover the most accessible areas of Australia and the last two cover the 
most remote areas. 
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Example 1: High total cholesterol 
In order for the survey to be able to identify a particular risk factor in the 
blood that has a prevalence of 50% with a 95% confidence interval range from 
45% to 55%, an estimated total of 12,229 blood samples would be required to 
provide estimates for the following age/sex groups from 12 to 74 years (12-17, 
18-24, 35-44, 45-55, 55-64 and 65-74 years). 
That is, just over 1,000 blood samples are required per age/sex group to 
report the finding, for example, that 50% of a particular age group (by sex) 
has a high total cholesterol (5.5 mmol/l or higher), (95% confidence interval 
from 45% to 55%).  Note that these estimates apply to each of the age/sex 
groups 12-17, 18-24, 35-44, 45-54, 55-64, and 65-74 years.   
Example 2: Depressed HDL-cholesterol levels 
In order for the survey to be able to identify a particular risk factor in the 
blood that has a prevalence of 10% with a 95% confidence interval range from 
7% to 13%, an estimated 9,662 blood samples would be required to provide 
estimates for the following age/sex groups from 12 to 74 years (12-17, 18-24, 
35-44, 45-55, 55-64 and 65-74 years). 
That is, a total of 9,662 blood samples are required to report the finding that 
10% of a particular age group (by sex) has depressed HDL-cholesterol (<1.0 
mmol/l), with a 95% confidence interval from 7% to 13%.  Note that these 
estimates apply to each of the age/sex groups 12-17, 18-24, 35-44, 45-54, 55-64, 
and 65-74 years.   
Table 5.1:  Sample size estimates for selected prevalence rates 
Examples Blood Samples 
Prevalence: 50% ± 5% 
Age groups1 by sex 
12,229 
Prevalence: 10% ± 3% 
Age groups1 by sex 
9,662 
1 Age groups 12-17, 18-24, 35-44, 45-54, 55-64, and 65-74 years. 
Note: These estimates incorporate a design (or cluster) effect of 1.6 in the high 
prevalence (50%) example. 
Under the design outlined in Table 5.2 (below) the sample size would be 
insufficient to achieve the level of precision for the estimated prevalence in 
Example 1 (high total cholesterol).  However, it would be possible to estimate 
this variable with a lower level of precision (± 6%, rather than ± 5%).  In this 
case, a 95% confidence interval ranging from 44% to 56% would require an 
estimated 8,504 blood samples, which is within the number estimated from 
the sample size proposed.   
In light of this analysis, it was determined that around 10,000 blood samples 
were required.  This would also allow the detection of trends over time by 
comparing with past estimates.  
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5.4.3 Estimates of response rates by type of measurement 
The AHMS sample will be drawn from the NHS sample.  The 2001 NHS 
sample comprised 24,000 private dwellings with a possible 26,980 people 
being interviewed (8,200 aged from 0 to 17 years and 18,800 aged 18 years and 
over).  The 2004/5 sample is expected to be of a similar size. 
Estimates of response at each stage from the NHS interview to the taking of 
physical and biochemical measurements are presented in Table 5.2.  They are 
based on the 2001 NHS sample (adjusted to exclude people aged 75 years and 
over, or under two years of age); the likely response rate in the NHS; the 
response rate achieved in the AHMS skirmish; and an estimated response 
drop between measurements at the nurse visit (based on response data from 
the Health Survey for England).  It has been assumed that 90% of people who 
complete the NHS interview will be asked to participate in the AHMS.   
Subject to the achievement of these levels of response (and the impact of any 
requirement for fasting, as discussed below), this design would deliver the 
sample size required to provide the number of blood samples in the examples 
presented above.  More details of the calculations in Table 5.2 are in Appendix 
G.  
It should be noted that the skirmish did not involve advice to participants that 
they would be required to fast before the taking of samples.  However, if 
measures from the AHMS were to be comparable with those from earlier 
surveys (which used fasting samples), at least a sub-sample of the AHMS 
samples would need to be fasting.  The requirement for fasting, and the 
number of hours of fasting required (e.g. eight hours as recommended by the 
WHO, or 12 hours as is usually the case in Australia), are yet to be determined.  
The proposed pilot test will need to ascertain the impact that fasting has on 
recruitment to the AHMS and on obtaining the fasting samples (and the 
impact on response rates) and the number of nurse visits needed to achieve 
fasting samples (and the impact on costs)4.  
 
                                                 
4 Note that the HSE response rate data used to estimate response drop between 
measurements are from a non-fasting sample.   
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Table 5.2:  Estimated response to the AHMS program 
ABS NHS  Children & youth Adults Total 
 2-11 12-17 18+ 
ABS NHS:  
Estimate of people fully responding  4,519 2,457 18,017 24,993
AHMS (recruitment and nurse visit):  
Asked to participate in AHMS1 4,067 2,211 16,215 22,494
Consented to see a nurse 2,981 1,621 10,602 15,204
Measurements taken  
had height, weight measured 2,945 1,601 10,426 14,972
had waist-hip measured 2,945 1,601 10,422 14,969
had BP measured 2,910 1,582 10,422 14,914
gave a saliva sample (from age 4 years) 2,910 1,582 10,242 14,734
agreed to give a blood sample n.a. 1,360 8,805 10,165
gave a blood sample n.a. 1,304 8,446 9,750



































6.  ETHICAL ISSUES 
 
The ethical, legal and social issues that arise from a survey program of this 
kind are numerous, and will be determined largely by the survey design and 
its implementation. A range of ethical issues was identified as part of the 
developmental process for the AHMS program and is contained in Appendix 
F.  A number of broad policy issues emerge that will require discussion and 
resolution during the further development of the proposed AHMS program.  
 
6.1   Ethical overview 
In Australia, research involving human participation must be conducted in 
accordance with agreed ethical considerations as set out in the National 
Statement on Ethical Conduct in Research Involving Humans (NHMRC 1999). 
Research must be so designed that respect for the dignity and well being of 
participants takes precedence over the expected benefits to knowledge 
(NHMRC 2000). Research involving human participation is also subject to a 
variety of legal requirements at Federal, State and Territory levels.  All 
research must comply with any relevant Commonwealth and State/Territory 
legislation (NHMRC 2000). 
The process of conducting a national population health survey using physical 
and biochemical measures leads to ethical issues arising at each step in the 
process.  For example, the design of the survey program, once agreed, will 
have ethical issues peculiar to it.  The selection of children for inclusion in the 
sampling frame, subject recruitment, the choice of specific content areas and 
their selected forms of measurement, and the issues surrounding the feedback 
of results to participants, all have ethical implications.  Informed consent and 
its scope, confidentiality and privacy of information are also important 
considerations.  
Participants in the survey program and the Australian community as a whole 
must be assured that each of these areas has been examined in detail and 
ethical considerations addressed. There is a responsibility to involve 
community members in the identification of ethical issues and in finding 
satisfactory solutions to resolve them. A range of strategies can be employed 
to undertake this, from consultation with consumer organisations and 
community representatives, to the use of focus groups and cognitive testing, 
to pilot testing of the survey processes.  
Consumer involvement in a survey of this kind will be critical in determining 
its success, given the response rates that are needed to ensure that sampling is 
representative of the population(s) of interest.  Significant investment will be 
required to encourage consumer participation and support at every stage of 
the survey.  Consumer confidentiality and privacy concerns will require a 
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concerted effort and a planned strategy to ensure issues of data collection, 
storage, security and access to researchers for analyses are handled ethically.  
Consumer anxieties are also likely to be heightened when sampling, 
particularly of blood, is initially raised in the public domain.  The benefits of 
the survey and aspects of the methodology will need to be asserted and 
discussed fully, and community confidence maintained if the AHMS program 
is to achieve its objectives and thus benefit the Australian community. 
There are a number of ways to proceed. Clearly each of the issues identified 
above requires careful thought and discussion. Existing Australian ethical 
guidelines will provide direction in some areas (NHMRC 1991). Advice will 
also be sought from researchers and agencies in Australia and overseas who 
have experience in the conduct of surveys of this kind. The determination of 
the most appropriate solutions will be part of the more detailed planning of 
the survey, which will be required if agreement in principle is gained from 
AHMAC.  
A continuing process of consultation with consumer organisations, ethnic and 
Indigenous groups, and community representatives will also be required to 
explore community attitudes and concerns about ethical issues, and to 
determine the way to proceed with the survey program’s development and 
execution. Ultimately, any proposed survey will be subject to the usual 
processes of ethical oversight by an Institutional Ethics Committee before it 
can commence. It has been suggested that this be the AIHW Ethics 
Committee, given that it is likely that the AIHW will have oversight of the 
further development of the AHMS program. 
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7.  OUTPUTS FROM THE AHMS PROGRAM 
 
The data collected by the AHMS program will be a unique resource for 
policy-makers and researchers working within government and non-
government organisations, educational facilities and other research institutes.  
The NHANES program in the US, for example, has been very successful at 
generating value added research with over 200 journal publications using its 
name in their titles from 1997-1998 alone.  In order to maximise the research 
opportunities associated with the AHMS program, arrangements for access to 
survey data will need to be put in place.   
7.1   Data access 
 
Results from the NHS and the combined NHS/AHMS will only be available 
from the ABS.    Due to confidentiality requirements, the ABS will not release 
a confidentialised unit record file (CURF). 
 
The ABS will facilitate access to the data in a number of ways.  These include: 
1. ABS to undertake tabulations to user specifications on a cost recovery 
basis. 
2. ABS to work jointly with research analysts on specific projects and papers, 
which are identified as being significant for research. 
3. The development of a synthetic survey data file designed to enable 
preparation and testing of programs for remote submission to the ABS 
data laboratory. 
4. Remote submission of user generated programs using software, such as 
SAS and SPSS, to the ABS data laboratory.  ABS will monitor outputs from 




A dissemination strategy will be developed jointly by DoHA, ABS, AIHW 
and other major stakeholders.  This strategy will define in some detail the 
publications and spreadsheets to be released from the AHMS data on its own 
and in conjunction with the NHS data. 
 
It is expected that the ABS and the AIHW will both publish a range of reports 
using the AHMS data.  The initial publication from the combined 
AHMS/NHS results will be released by the ABS. Based on the agreed 
dissemination strategy, AIHW will release a series of reports focusing on the 
AHMS data.  As well these publications will be complemented by reports 
prepared by AIHW, DoHA and other research analysts under the access 




8.  FURTHER DEVELOPMENT AND MANAGEMENT OF 
THE AHMS PROGRAM 
 
There is a range of issues that require further work, development and 
decisions if the first survey of the AHMS program is to be conducted for the 
first time in 2004/5, together with the NHS.   
They include: 
• ethical and legal issues; 
• professional and consumer consultations;  
• AHMS publicity/marketing; 
• data and sample ownership; 
• data access issues; 
• AHMS questionnaire development; 
• development of AHMS documentation (measurement and sample 
collection protocols); 
• conduct of a pilot test and dress rehearsal;  
• AHMS fieldwork; and 
• data analysis, dissemination and reporting. 
The work can be divided into three separate stages:  
1) survey development,  
2) conduct of the survey, and  
3) data analysis, dissemination and reporting.   
It is envisaged that the work on the AHMS will be led by DoHA in strategic 
partnership with AIHW and in close cooperation with ABS.   
An outline of how the work on the AHMS program is proposed to be 
managed through these three stages follows. 
 
8.1   Stage 1 – Survey Development 
Work on the development of the AHMS program will continue through the 
2002/3 and 2003/4 financial years.  By the end of 2003/4, the first AHMS is 
expected to be fully developed and ready to enter the next stage focused on 
the conduct of the survey.  Stage 1 will involve the development of a detailed 
timeframe and the conduct of a pilot test in 2002/3 and a dress rehearsal in 
2003/4.  The NHS is due to commence in late July or early August 2004/5.   
It is likely that some aspects of the developmental work, such as the 
development of the questionnaire and the measurement and sample 
collection protocols, will continue beyond 2002/3, in order to take into 
account the outcomes of a pilot test.  Some work relating to promoting the 
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survey to the public in order to ensure as high as possible response rate may 
also be carried out closer to the commencement of the survey.   
The developmental phase will require the cooperation of the partnership 
agencies, namely the DoHA and the AIHW, as well as the close involvement of 
the ABS.  Considerable technical expertise will also be required.  States and 
Territories will be involved through the NHIMG and the NPHIWG.   
Two groups will oversee development and implementation of the Survey: a 
new AHMS Reference Group and the AHMS Project Group.  Their functions 
and composition are outlined below. 
AHMS Reference Group 
Role 
The role of the Reference Group will be an advisory one.  The Reference 
Group will provide strategic policy, scientific and technical directions for the 
AHMS program and ensure that input is provided through consultations with 
the jurisdictions, scientific and technical experts, consumers and non-
government organisations, and that all relevant issues are considered and 
endorsements and decisions are sought as appropriate. 
The Terms of Reference for the Reference Group will be developed to provide 
quality assurance for the first survey and to provide advice on issues involved 
in survey development, conduct of the survey, and data analysis and 
reporting. 
Composition 
The AHMS Reference Group will include representatives/nominees from: 
1. Jurisdictional representatives 
- DoHA (one of them to chair the Committee) 
- AIHW 
- ABS 
- NPHIWG (3-4 State/Territory representatives) 
- National Health Priority Action Council 
2. Non-Government Organisations and Consumers, for example 
- National Heart Foundation 
- Consumers Health Forum 
3. Scientific and Technical Experts 
- Members of the former Scientific Reference Group, as required. 
Modus operandi 
It is envisaged that the Reference Group will be flexible in the way it 
functions, and cost-efficient.  It is anticipated that input from the Reference 
Group will be sought on particular issues as needed in a way that is the most 
suitable and practical to progress the development of the AHMS in a timely 
manner. 
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AHMS Project Group 
The AHMS Project Group will be a senior executive level group consisting of 
1-2 representatives of the DoHA, AIHW and ABS.  Their role will be to grant 
final approval to matters relating to the AHMS program development and 
conduct that require decisions or directions from senior executive level in the 
DoHA, AIHW and ABS.  
Some specific issues that the AHMS Project Group will be expected to 
approve relate to a tendering process, including approval of the tender brief 
and selection of a subcontractor.   
8.2   Stage 2 – Conduct of Field Work  
The management of the AHMS fieldwork will rest with the AIHW.  The MoU 
between the DoHA and the AIHW will provide a vehicle for relevant 
arrangements between the two agencies.  The AIHW will sub-contract the 
conduct of the survey to another agency (such as a University) and will have 
high-level oversight of the management, the subcontracting arrangements 
and of the day-to-day conduct of the AHMS program.   
To progress the first survey, and to guide and assist the AIHW, the AHMS 
Reference Group and the AHMS Project Group will continue through stages 2 
and 3, providing quality assurance and problem solving functions. 
 
8.3   Stage 3 – Data Analysis, Reporting and 
Dissemination 
In addition to the data held by the ABS and disseminated as noted in Section 
7.1, it is expected that a range of post-survey work will be undertaken by the 
AIHW under the MoU arrangements with DoHA.  The scope and details of 
the work to be carried out will be determined at a later stage, in accordance 




9.  ESTIMATED COST OF THE FIRST SURVEY  
 
An estimate has been made of the cost of conducting the first survey in the 
AHMS program in association with the 2004/5 NHS.  A number of 
assumptions have been made in producing the estimate.  These include the 
number of staff working in the agency contracted to conduct the AHMS (4 
FTE); the period over which survey development, conduct and reporting 
would occur (including 12 months prior to the survey, the survey period of 
approximately 44 weeks and 8 months subsequent); the rate of recruitment of 
NHS respondents to the measurement phase and their rate of retention for 
each of the measures; the impact of fasting on recruitment and on the number 
of call backs needed for the nurse to obtain valid blood samples; the number 
of nurses required to conduct the measurement phase; the cost of equipment 
and laboratory analyses; and the cost of reporting, including the provision of 
results of the measurements to participants, or their general medical 
practitioner.  Details of the assumptions made in preparing the estimates are 
shown in Appendix G.   
Some of the estimates are based on relatively firm information and others are 
subject to greater error until a detailed pilot test is undertaken.  For example, 
the cost of nurses is based on a weekend rate for a nurse trained in 
venepuncture, and the estimate is likely to be relatively reliable.  The estimate 
of the number of nurses that will be required is less so.  It will depend on a 
number of factors, including the number of contacts required to make an 
appointment and the time taken to complete the measurements at each 
dwelling.  If, as is likely, participants will be required to fast before the 
measurements are taken, the nurse will need to re-schedule the appointment 
where the participant fails to fast.  This could add considerably to the cost of 
the nurse visits.  The other large cost item in the budget is the cost of analyses 
of the samples.  The list of analyses on which the quote was based (Appendix 
G) is more extensive than is likely to be required in the survey.  With a 
smaller number of tests, and under competitive tendering, these costs are 
likely to be lower.  When a decision is made as to the final range of measures 
to be taken, it will be possible to obtain a better estimate.   
As noted, the estimates include the cost of providing a telephone information 
line during the conduct of the survey for participants or potential participants 
in the AHMS to seek information regarding the survey.  They also include the 
cost of providing results of the measurements to the participant or their 
general medical practitioner, on the participant’s advice.  No provision has 
been made for participants to contact AHMS staff to discuss their results.  
However, the report of the results will include general advice as to steps that 
participants might take in relation to their particular results.   
The estimated cost of conducting the first survey in the AHMS program is 
$6.3 million (excluding GST) (see Table 9.1).  These costs include the conduct 
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of a dress rehearsal; pilot test costs are being met separately. It is anticipated 
that the management of the AHMS program will be undertaken by the AIHW 
who will manage the development process (including community and 
professional consultations), the conduct of the survey, and the secretariat to 
the new Reference Group.  These costs have not been included in Table 9.1, 
but with their inclusion, the total cost rises to $7.2 million.  With a program 
cycle of six years, this equates to a cost of $1.2 million per annum. 
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Table 9.1:  Australian Health Measurement Survey Costs 
Component Estimated 
Costs ($m) 
Survey development & conduct  
Staff – Director and support staff (4 FTE over 2.5 years) ) 
Data specification, client liaison ) 
Measurement protocols, training manuals ) 
Coding manuals (with ABS involvement) ) 1.1 
Specification of edit checks for measurements, samples; etc. ) 
Editing ) 
Weighting ) 
Data preparation (assuming CAPI collection)  0.05 
Publicity & Promotion  0.1 
Analysis ) 
Reporting – publications (incl. printing) ) 0.1 
Web site development/ maintenance ) 
Survey info line & reporting – written feed back to respondents/ GPs  0.1 
Payment to ABS  
Respondent recruitment & non-response adjustment ) 0.17 
Output processing and data handling ) 0.09 
Client support and dissemination ) 0.28 
Field costs: measurements (incl. staff on costs & insurances)  
Recruitment & training of nurses ) 
In-home time (measurements) (incl. mileage) ) 
Non-response follow-up ) 1.78 
Supervision/ quality checks ) 
Equipment (scales, sphygmomanometer, etc.) ) 
Samples  
Bottles, needles etc. ) 
Local storage, collection & transport ) 1.57 
Laboratory analysis & reporting ) 
Survey developmental and operational costs  5.34 
Dress rehearsal  0.38 
Contingency – 10%  0.57 
Total Survey Costs excluding GST  6.3 
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